Kyle Chamberlain

Q: What is Kyle Chamberlain email address?

Email Kyle Chamberlain at kyle.chamberlain@mssm.edu. This email is the most updated Kyle Chamberlain email found in 2026.

Q: How to contact Kyle Chamberlain?

To contact Kyle Chamberlain send an email to kyle.chamberlain@mssm.edu. If you want to call Kyle Chamberlain try calling on +12018999917.

Senior Scientist at Affinia Therapeutics | Bedford, Massachusetts, United States

About Kyle Chamberlain

Kyle Chamberlain is a Senior Scientist at Affinia Therapeutics, where he plays a pivotal role in advancing the company's mission to develop innovative gene therapies for rare genetic disorders. With over nine years of experience in molecular biology, virology, and gene therapy, Kyle has established himself as a leader in translational biology, bridging the gap between laboratory research and clinical application. His expertise encompasses a wide array of techniques, including polymerase chain reaction (PCR), virus purification, and cloning, which he employs to optimize gene delivery systems and enhance therapeutic efficacy.

At Affinia, Kyle spearheads several key projects focused on the development of adeno-associated virus (AAV) vectors for targeted gene therapy applications. His work involves meticulous design and execution of experiments that assess the safety and efficacy of these vectors in preclinical models. By leveraging advanced microscopy techniques and SDS-PAGE analysis, he ensures the integrity and functionality of viral preparations, which are critical for successful clinical trials.

Kyle is also dedicated to fostering a collaborative research environment, effectively communicating complex scientific concepts to cross-functional teams and stakeholders. His commitment to mentorship in student affairs reflects his passion for nurturing the next generation of scientists. As a Principal Scientist, Kyle continues to push the boundaries of gene therapy, striving to deliver innovative solutions that hold the potential to transform the lives of patients with rare diseases. His contributions not only enhance Affinia's research portfolio but also position the company at the forefront of the biotechnology industry.

Kyle Chamberlain Work